Rabies Virus as a Research Tool and Viral Vaccine Vector

Advances in Virus Research

Volumn 79, Issue , 2011, Pages 139-164

  Gomme, Emily A ^a   Wanjalla, Celestine N ^a   Wirblich, Christoph ^a   Schnell, Matthias J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Antigen presentation; Neuronal tracer; Rabies virus; Single cycle vector; Vaccine vector

Indexed keywords

DRUG CARRIER; VIRUS VACCINE;

ANIMAL; BOOK; GENE VECTOR; GENETIC ENGINEERING; GENETICS; HUMAN; IMMUNOLOGY; METHODOLOGY; MICROBIAL GENETICS; RABIES VIRUS;

ANIMALS; DRUG CARRIERS; GENETIC ENGINEERING; GENETIC VECTORS; GENETICS, MICROBIAL; HUMANS; RABIES VIRUS; VIRAL VACCINES;

EID: 79956122572     PISSN: 00653527     EISSN: 15578399     Source Type: Book Series    
DOI: 10.1016/B978-0-12-387040-7.00009-3     Document Type: Book

References (131)

1. The prevention, control and eradication of rabies in Europe. Dev. Biol. (Basel) 2006, 125:291-296. Anonymous.
2. Astic L., Saucier D., Coulon P., Lafay F., Flamand A. The CVS strain of rabies virus as transneuronal tracer in the olfactory system of mice. Brain Res. 1993, 619(1-2):146-156.
3. Bozac A., Berto E., Vasquez F., Grandi P., Caputo A., Manservigi R., Ensoli B., Marconi P. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine 2006, 24(49-50):7148-7158.
4. Buttner-Ennever J.A., Horn A.K., Graf W., Ugolini G. Modern concepts of brainstem anatomy: From extraocular motoneurons to proprioceptive pathways. Ann. NY Acad. Sci. 2002, 956:75-84.
5. Callaway E.M. Transneuronal circuit tracing with neurotropic viruses. Curr. Opin. Neurobiol. 2008, 18(6):617-623.
6. Cenna J., Tan G.S., Papaneri A.B., Dietzschold B., Schnell M.J., McGettigan J.P. Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 2008, 26(50):6405-6414.
7. Cenna J., Hunter M., Tan G.S., Papaneri A.B., Ribka E.P., Schnell M.J., Marx P.A., McGettigan J.P. Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J. Infect. Dis. 2009, 200(8):1251-1260.
8. Clower D.M., Dum R.P., Strick P.L. Basal ganglia and cerebellar inputs to 'AIP'. Cereb. Cortex 2005, 15(7):913-920.
9. Conzelmann K.K., Schnell M. Rescue of synthetic genomic RNA analogs of rabies virus by plasmid-encoded proteins. J. Virol. 1994, 68(2):713-719.
10. Conzelmann K.K., Cox J.H., Schneider L.G., Thiel H.J. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 1990, 175(2):485-499.
11. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 2005, 341(1):91-101.
12. Coulon P., Derbin C., Kucera P., Lafay F., Prehaud C., Flamand A. Invasion of the peripheral nervous systems of adult mice by the CVS strain of rabies virus and its avirulent derivative AvO1. J. Virol. 1989, 63(8):3550-3554.
13. Coulon P., Ternaux J.P., Flamand A., Tuffereau C. An avirulent mutant of rabies virus is unable to infect motoneurons in vivo and in vitro. J. Virol. 1998, 72(1):273-278.
14. Dietzschold B., Schnell M.J. New approaches to the development of live attenuated rabies vaccines. Hybrid. Hybridomics 2002, 21(2):129-134.
15. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., Koprowski H. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 1983, 80(1):70-74.
16. Dietzschold B., Faber M., Schnell M.J. New approaches to the prevention and eradication of rabies. Expert Rev. Vaccines 2003, 2(3):399-406.
17. Dietzschold B., Schnell M., Koprowski H. Pathogenesis of rabies. Curr. Top. Microbiol. Immunol. 2005, 292:45-56.
18. Dietzschold B., Li J., Faber M., Schnell M. Concepts in the pathogenesis of rabies. Future Virol. 2008, 3(5):481-490.
19. Durali D., Morvan J., Letourneur F., Schmitt D., Guegan N., Dalod M., Saragosti S., Sicard D., Levy J.P., Gomard E. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients. J. Virol. 1998, 72(5):3547-3553.
20. Etessami R., Conzelmann K.K., Fadai-Ghotbi B., Natelson B., Tsiang H., Ceccaldi P.E. Spread and pathogenic characteristics of a G-deficient rabies virus recombinant: An in vitro and in vivo study. J. Gen. Virol. 2000, 81(Pt 9):2147-2153.
21. Faber M., Pulmanausahakul R., Hodawadekar S.S., Spitsin S., McGettigan J.P., Schnell M.J., Dietzschold B. Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response. J. Virol. 2002, 76(7):3374-3381.
22. Faber M., Pulmanausahakul R., Nagao K., Prosniak M., Rice A.B., Koprowski H., Schnell M.J., Dietzschold B. Identification of viral genomic elements responsible for rabies virus neuroinvasiveness. Proc. Natl. Acad. Sci. USA 2004, 101(46):16328-16332.
23. Faber M., Bette M., Preuss M.A., Pulmanausahakul R., Rehnelt J., Schnell M.J., Dietzschold B., Weihe E. Overexpression of tumor necrosis factor alpha by a recombinant rabies virus attenuates replication in neurons and prevents lethal infection in mice. J. Virol. 2005, 79(24):15405-15416.
24. Faber M., Faber M.L., Papaneri A., Bette M., Weihe E., Dietzschold B., Schnell M.J. A single amino acid change in rabies virus glycoprotein increases virus spread and enhances virus pathogenicity. J. Virol. 2005, 79(22):14141-14148.
25. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., Schnell M.J. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J. Gen. Virol. 2005, 86(Pt 5):1435-1440.
26. Faber M., Li J., Kean R.B., Hooper D.C., Alugupalli K.R., Dietzschold B. Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl. Acad. Sci. USA 2009, 106(27):11300-11305.
27. Faul E.J., Wanjalla C.N., McGettigan J.P., Schnell M.J. Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity. Virology 2008, 382(2):226-238.
28. Faul E., Lyles D., Schnell M. Interferon response and viral evasion by members of the family Rhabdoviridae. Viruses 2009, 1(3):832-851.
29. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., Chervoneva I., Montefiori D.C., Lackner A.A., Schnell M.J. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28(2):299-308.
30. Foley H.D., McGettigan J.P., Siler C.A., Dietzschold B., Schnell M.J. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc. Natl. Acad. Sci. USA 2000, 97(26):14680-14685.
31. Foley H.D., Otero M., Orenstein J.M., Pomerantz R.J., Schnell M.J. Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells. J. Virol. 2002, 76(1):19-31.
32. Gillet J.P., Derer P., Tsiang H. Axonal transport of rabies virus in the central nervous system of the rat. J. Neuropathol. Exp. Neurol. 1986, 45(6):619-634.
33. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J. Virol. 2010, 84(6):2820-2831.
34. Graf W., Gerrits N., Yatim-Dhiba N., Ugolini G. Mapping the oculomotor system: The power of transneuronal labelling with rabies virus. Eur. J. Neurosci. 2002, 15(9):1557-1562.
35. Grimm R. The history of the eradication of rabies in most European countries. Hist. Med. Vet. 2002, 27(1-4):295-301.
36. Hashimoto M., Takahara D., Hirata Y., Inoue K., Miyachi S., Nambu A., Tanji J., Takada M., Hoshi E. Motor and non-motor projections from the cerebellum to rostrocaudally distinct sectors of the dorsal premotor cortex in macaques. Eur. J. Neurosci. 2010, 31(8):1402-1413.
37. Haut L.H., Ertl H.C. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J. Leukoc. Biol. 2009, 86(4):779-793.
38. Hoshi E., Tremblay L., Feger J., Carras P.L., Strick P.L. The cerebellum communicates with the basal ganglia. Nat. Neurosci. 2005, 8(11):1491-1493.
39. Huang Y., Tang Q., Nadin-Davis S.A., Zhang S., Hooper C.D., Ming P., Du J., Tao X., Hu R., Liang G. Development of a reverse genetics system for a human rabies virus vaccine strain employed in China. Virus Res. 2010, 149(1):28-35.
40. Inoue K., Shoji Y., Kurane I., Iijima T., Sakai T., Morimoto K. An improved method for recovering rabies virus from cloned cDNA. J. Virol. Methods 2003, 107(2):229-236.
41. Ito N., Takayama M., Yamada K., Sugiyama M., Minamoto N. Rescue of rabies virus from cloned cDNA and identification of the pathogenicity-related gene: Glycoprotein gene is associated with virulence for adult mice. J. Virol. 2001, 75(19):9121-9128.
42. Ito N., Sugiyama M., Yamada K., Shimizu K., Takayama-Ito M., Hosokawa J., Minamoto N. Characterization of M gene-deficient rabies virus with advantages of effective immunization and safety as a vaccine strain. Microbiol. Immunol. 2005, 49(11):971-979.
43. Iwata K., Miyachi S., Imanishi M., Tsuboi Y., Kitagawa J., Teramoto K., Hitomi S., Shinoda M., Kondo M., Takada M. Ascending multisynaptic pathways from the trigeminal ganglion to the anterior cingulate cortex. Exp. Neurol 2011, 227(1):69-78.
44. Jacotot E., Cardona A., Rebouillat D., Terradillos O., Marianneau P., Thoulouze M.I., Lafon M., Deubel V., Edelman L. Combined use of radioimagers and radioactive 3'OH DNA nick end labelling to quantify apoptosis in cell lines and tissue sections: Applications to virus-induced apoptosis. Apoptosis 1999, 4(3):169-178.
45. Karacostas V., Nagashima K., Gonda M.A., Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc. Natl. Acad. Sci. USA 1989, 86(22):8964-8967.
46. Kelly R.M., Strick P.L. Rabies as a transneuronal tracer of circuits in the central nervous system. J. Neurosci. Methods 2000, 103(1):63-71.
47. Kelly R.M., Strick P.L. Cerebellar loops with motor cortex and prefrontal cortex of a nonhuman primate. J. Neurosci. 2003, 23(23):8432-8444.
48. Kelly R.M., Strick P.L. Macro-architecture of basal ganglia loops with the cerebral cortex: Use of rabies virus to reveal multisynaptic circuits. Prog. Brain Res. 2004, 143:449-459.
49. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., McDermott A.B., Schultz A., Zamb T.J., Boyle R., Desrosiers R.C. HIV vaccine design: Insights from live attenuated SIV vaccines. Nat. Immunol. 2006, 7(1):19-23.
50. Koser M.L., McGettigan J.P., Tan G.S., Smith M.E., Koprowski H., Dietzschold B., Schnell M.J. Rabies virus nucleoprotein as a carrier for foreign antigens. Proc. Natl. Acad. Sci. USA 2004, 101(25):9405-9410.
51. Kuang Y., Lackay S.N., Zhao L., Fu Z.F. Role of chemokines in the enhancement of BBB permeability and inflammatory infiltration after rabies virus infection. Virus Res. 2009, 144(1-2):18-26.
52. Kucera P., Dolivo M., Coulon P., Flamand A. Pathways of the early propagation of virulent and avirulent rabies strains from the eye to the brain. J. Virol. 1985, 55(1):158-162.
53. Lafay F., Coulon P., Astic L., Saucier D., Riche D., Holley A., Flamand A. Spread of the CVS strain of rabies virus and of the avirulent mutant AvO1 along the olfactory pathways of the mouse after intranasal inoculation. Virology 1991, 183(1):320-330.
54. Langley W.A., Bradley K.C., Li Z.N., Smith M.E., Schnell M.J., Steinhauer D.A. Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: Implications for disparate immune system priming pathways. J. Virol. 2010, 84(16):8300-8307.
55. Larsen D.D., Wickersham I.R., Callaway E.M. Retrograde tracing with recombinant rabies virus reveals correlations between projection targets and dendritic architecture in layer 5 of mouse barrel cortex. Front. Neural Circuits 2007, 1:5.
56. Le Mercier P., Jacob Y., Tanner K., Tordo N. A novel expression cassette of lyssavirus shows that the distantly related Mokola virus can rescue a defective rabies virus genome. J. Virol. 2002, 76(4):2024-2027.
57. Lentz T.L., Burrage T.G., Smith A.L., Tignor G.H. The acetylcholine receptor as a cellular receptor for rabies virus. Yale J. Biol. Med. 1983, 56(4):315-322.
58. Li J., McGettigan J.P., Faber M., Schnell M.J., Dietzschold B. Infection of monocytes or immature dendritic cells (DCs) with an attenuated rabies virus results in DC maturation and a strong activation of the NFkappaB signaling pathway. Vaccine 2008, 26(3):419-426.
59. Lois J.H., Rice C.D., Yates B.J. Neural circuits controlling diaphragm function in the cat revealed by transneuronal tracing. J. Appl. Physiol. 2009, 106(1):138-152.
60. McAdam S., Kaleebu P., Krausa P., Goulder P., French N., Collin B., Blanchard T., Whitworth J., McMichael A., Gotch F. Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection. AIDS 1998, 12(6):571-579.
61. McGettigan J.P. Experimental rabies vaccines for humans. Expert Rev. Vaccines 2010, 9(10):1177-1186.
62. McGettigan J.P., Foley H.D., Belyakov I.M., Berzofsky J.A., Pomerantz R.J., Schnell M.J. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates. J. Virol. 2001, 75(9):4430-4434.
63. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 2001, 75(18):8724-8732.
64. McGettigan J.P., Naper K., Orenstein J., Koser M., McKenna P.M., Schnell M.J. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and Env expressed from a single rhabdovirus-based vaccine vector genome. J. Virol. 2003, 77(20):10889-10899.
65. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., Schnell M.J. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J. Virol. 2003, 77(1):237-244.
66. McGettigan J.P., Koser M.L., McKenna P.M., Smith M.E., Marvin J.M., Eisenlohr L.C., Dietzschold B., Schnell M.J. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. Virology 2006, 344(2):363-377.
67. McKenna P.M., Pomerantz R.J., Dietzschold B., McGettigan J.P., Schnell M.J. Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes. J. Virol. 2003, 77(23):12782-12794.
68. McKenna P.M., Aye P.P., Dietzschold B., Montefiori D.C., Martin L.N., Marx P.A., Pomerantz R.J., Lackner A., Schnell M.J. Immunogenicity study of glycoprotein-deficient rabies virus expressing simian/human immunodeficiency virus SHIV89.6P envelope in a rhesus macaque. J. Virol. 2004, 78(24):13455-13459.
69. McKenna P.M., Koser M.L., Carlson K.R., Montefiori D.C., Letvin N.L., Papaneri A.B., Pomerantz R.J., Dietzschold B., Silvera P., McGettigan J.P., Schnell M.J. Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J. Infect. Dis. 2007, 195(7):980-988.
70. Mebatsion T. Extensive attenuation of rabies virus by simultaneously modifying the dynein light chain binding site in the P protein and replacing Arg333 in the G protein. J. Virol. 2001, 75(23):11496-11502.
71. Mebatsion T., Conzelmann K.K. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc. Natl. Acad. Sci. USA 1996, 93(21):11366-11370.
72. Mebatsion T., Konig M., Conzelmann K.K. Budding of rabies virus particles in the absence of the spike glycoprotein. Cell 1996, 84(6):941-951.
73. Mebatsion T., Schnell M.J., Cox J.H., Finke S., Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc. Natl. Acad. Sci. USA 1996, 93(14):7310-7314.
74. Mebatsion T., Finke S., Weiland F., Conzelmann K.K. A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells. Cell 1997, 90(5):841-847.
75. Mebatsion T., Weiland F., Conzelmann K.K. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 1999, 73(1):242-250.
76. Morcuende S., Delgado-Garcia J.M., Ugolini G. Neuronal premotor networks involved in eyelid responses: Retrograde transneuronal tracing with rabies virus from the orbicularis oculi muscle in the rat. J. Neurosci. 2002, 22(20):8808-8818.
77. Morimoto K., Hooper D.C., Spitsin S., Koprowski H., Dietzschold B. Pathogenicity of different rabies virus variants inversely correlates with apoptosis and rabies virus glycoprotein expression in infected primary neuron cultures. J. Virol. 1999, 73(1):510-518.
78. Morimoto K., Foley H.D., McGettigan J.P., Schnell M.J., Dietzschold B. Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach. J. Neurovirol. 2000, 6(5):373-381.
79. Morimoto K., McGettigan J.P., Foley H.D., Hooper D.C., Dietzschold B., Schnell M.J. Genetic engineering of live rabies vaccines. Vaccine 2001, 19(25-26):3543-3551.
80. Morimoto K., Shoji Y., Inoue S. Characterization of P gene-deficient rabies virus: Propagation, pathogenicity and antigenicity. Virus Res. 2005, 111(1):61-67.
81. Nassi J.J., Callaway E.M. Multiple circuits relaying primate parallel visual pathways to the middle temporal area. J. Neurosci. 2006, 26(49):12789-12798.
82. Ohara S., Inoue K., Yamada M., Yamawaki T., Koganezawa N., Tsutsui K., Witter M.P., Iijima T. Dual transneuronal tracing in the rat entorhinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors. Front. Neuroanat. 2009, 3:1.
83. Ohara S., Inoue K., Witter M.P., Iijima T. Untangling neural networks with dual retrograde transsynaptic viral infection. Front. Neurosci. 2009, 3(3):344-349.
84. Ohara S., Inoue K., Yamada M., Yamawaki T., Koganezawa N., Tsutsui K., Witter M.P., Iijima T. Dual transneuronal tracing in the rat entorhinal-hippocampal circuit by intracerebral injection of recombinant rabies virus vectors. Front. Neuroanat. 2009, 3:1.
85. Orbanz J., Finke S. Generation of recombinant European bat lyssavirus type 1 and inter-genotypic compatibility of lyssavirus genotype 1 and 5 antigenome promoters. Arch. Virol. 2010, 155(10):1631-1641.
86. Pasteur L. Methode pour prevenir la rage apres morsure. C. R. Acad. Sci. 1885, 101:765-773.
87. Peng B., Wang L.R., Gomez-Roman V.R., Davis-Warren A., Montefiori D.C., Kalyanaraman V.S., Venzon D., Zhao J., Kan E., Rowell T.J., Murthy K.K., Srivastava I., et al. Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies. J. Virol. 2005, 79(16):10200-10209.
88. Prevosto V., Graf W., Ugolini G. Posterior parietal cortex areas MIP and LIPv receive eye position and velocity inputs via ascending preposito-thalamo-cortical pathways. Eur. J. Neurosci. 2009, 30(6):1151-1161.
89. Publicover J., Ramsburg E., Rose J.K. A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector. J. Virol. 2005, 79(21):13231-13238.
90. Pulmanausahakul R., Faber M., Morimoto K., Spitsin S., Weihe E., Hooper D.C., Schnell M.J., Dietzschold B. Overexpression of cytochrome C by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. J. Virol. 2001, 75(22):10800-10807.
91. Pulmanausahakul R., Li J., Schnell M.J., Dietzschold B. The glycoprotein and the matrix protein of rabies virus affect pathogenicity by regulating viral replication and facilitating cell-to-cell spread. J. Virol. 2008, 82(5):2330-2338.
92. Rathelot J.A., Strick P.L. Muscle representation in the macaque motor cortex: An anatomical perspective. Proc. Natl. Acad. Sci. USA 2006, 103(21):8257-8262.
93. Rice C.D., Lois J.H., Kerman I.A., Yates B.J. Localization of serotoninergic neurons that participate in regulating diaphragm activity in the cat. Brain Res. 2009, 1279:71-81.
94. Rice C.D., Weber S.A., Waggoner A.L., Jessell M.E., Yates B.J. Mapping of neural pathways that influence diaphragm activity and project to the lumbar spinal cord in cats. Exp. Brain Res. 2010, 203(1):205-211.
95. Rolland M., Nickle D.C., Mullins J.I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007, 3(11):e157.
96. Roseveare C.W., Goolsby W.D., Foppa I.M. Potential and actual terrestrial rabies exposures in people and domestic animals, upstate South Carolina, 1994-2004: A surveillance study. BMC Public Health 2009, 9:65.
97. Ruigrok T.J., Pijpers A., Goedknegt-Sabel E., Coulon P. Multiple cerebellar zones are involved in the control of individual muscles: A retrograde transneuronal tracing study with rabies virus in the rat. Eur. J. Neurosci. 2008, 28(1):181-200.
98. Russell N.D., Graham B.S., Keefer M.C., McElrath M.J., Self S.G., Weinhold K.J., Montefiori D.C., Ferrari G., Horton H., Tomaras G.D., Gurunathan S., Baglyos L., et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a phase 3 correlates trial. J. Acquir. Immune Defic. Syndr. 2007, 44(2):203-212.
99. Schnell M.J., Mebatsion T., Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J. 1994, 13(18):4195-4203.
100. Schnell M.J., Foley H.D., Siler C.A., McGettigan J.P., Dietzschold B., Pomerantz R.J. Recombinant rabies virus as potential live-viral vaccines for HIV-1. Proc. Natl. Acad. Sci. USA 2000, 97(7):3544-3549.
101. Schnell M.J., McGettigan J.P., Wirblich C., Papaneri A. The cell biology of rabies virus: Using stealth to reach the brain. Nat. Rev. Microbiol. 2010, 8(1):51-61.
102. Shimizu K., Ito N., Mita T., Yamada K., Hosokawa-Muto J., Sugiyama M., Minamoto N. Involvement of nucleoprotein, phosphoprotein, and matrix protein genes of rabies virus in virulence for adult mice. Virus Res. 2007, 123(2):154-160.
103. Shoji Y., Inoue S., Nakamichi K., Kurane I., Sakai T., Morimoto K. Generation and characterization of P gene-deficient rabies virus. Virology 2004, 318(1):295-305.
104. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., Schnell M.J. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 2002, 292(1):24-34.
105. Smart N.L., Charlton K.M. The distribution of Challenge virus standard rabies virus versus skunk street rabies virus in the brains of experimentally infected rabid skunks. Acta Neuropathol. 1992, 84(5):501-508.
106. Smith M.E., Koser M., Xiao S., Siler C., McGettigan J.P., Calkins C., Pomerantz R.J., Dietzschold B., Schnell M.J. Rabies virus glycoprotein as a carrier for anthrax protective antigen. Virology 2006, 353(2):344-356.
107. Stepien A.E., Tripodi M., Arber S. Monosynaptic rabies virus reveals premotor network organization and synaptic specificity of cholinergic partition cells. Neuron 2010, 68(3):456-472.
108. Superti F., Hauttecoeur B., Morelec M.J., Goldoni P., Bizzini B., Tsiang H. Involvement of gangliosides in rabies virus infection. J. Gen. Virol. 1986, 67(Pt 1):47-56.
109. Taber K.H., Strick P.L., Hurley R.A. Rabies and the cerebellum: New methods for tracing circuits in the brain. J. Neuropsychiatry Clin. Neurosci. 2005, 17(2):133-139.
110. Tan G.S., McKenna P.M., Koser M.L., McLinden R., Kim J.H., McGettigan J.P., Schnell M.J. Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach. Virology 2005, 331(1):82-93.
111. Tan G.S., Preuss M.A., Williams J.C., Schnell M.J. The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription. Proc. Natl. Acad. Sci. USA 2007, 104(17):7229-7234.
112. Tellinghuisen T.L., Evans M.J., von Hahn T., You S., Rice C.M. Studying hepatitis C virus: Making the best of a bad virus. J. Virol. 2007, 81(17):8853-8867.
113. Thoulouze M.I., Lafage M., Schachner M., Hartmann U., Cremer H., Lafon M. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol. 1998, 72(9):7181-7190.
114. Tsiang H., Derer M., Taxi J. An in vivo and in vitro study of rabies virus infection of the rat superior cervical ganglia. Arch. Virol. 1983, 76(3):231-243.
115. Tuffereau C., Benejean J., Blondel D., Kieffer B., Flamand A. Low-affinity nerve-growth factor receptor (P75NTR) can serve as a receptor for rabies virus. EMBO J. 1998, 17(24):7250-7259.
116. Ugolini G. Specificity of rabies virus as a transneuronal tracer of motor networks: Transfer from hypoglossal motoneurons to connected second-order and higher order central nervous system cell groups. J. Comp. Neurol. 1995, 356(3):457-480.
117. Ugolini G. Advances in viral transneuronal tracing. J. Neurosci. Methods 2010, 194(1):2-20.
118. Ugolini G., Klam F., Doldan Dans M., Dubayle D., Brandi A.M., Buttner-Ennever J., Graf W. Horizontal eye movement networks in primates as revealed by retrograde transneuronal transfer of rabies virus: Differences in monosynaptic input to "slow" and "fast" abducens motoneurons. J. Comp. Neurol. 2006, 498(6):762-785.
119. Viemari J.C., Bevengut M., Burnet H., Coulon P., Pequignot J.M., Tiveron M.C., Hilaire G. Phox2a gene, A6 neurons, and noradrenaline are essential for development of normal respiratory rhythm in mice. J. Neurosci. 2004, 24(4):928-937.
120. Viemari J.C., Bevengut M., Coulon P., Hilaire G. Nasal trigeminal inputs release the A5 inhibition received by the respiratory rhythm generator of the mouse neonate. J. Neurophysiol. 2004, 91(2):746-758.
121. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132(2):667-678.
122. Wall N.R., Wickersham I.R., Cetin A., De La Parra M., Callaway E.M. Monosynaptic circuit tracing in vivo through Cre-dependent targeting and complementation of modified rabies virus. Proc. Natl. Acad. Sci. USA 2010, 107(50):21848-21853.
123. Wanjalla C.N., Faul E.J., Gomme E.A., Schnell M.J. Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity. Vaccine 2010, 29:130-140.
124. Wen Y., Wang H., Wu H., Yang F., Tripp R.A., Hogan R.J., Fu Z.F. Rabies virus expressing dendritic cell-activating molecules enhances the innate and adaptive immune response to vaccination. J. Virol 2010, 85:1634-1644.
125. Wickersham I.R., Finke S., Conzelmann K.K., Callaway E.M. Retrograde neuronal tracing with a deletion-mutant rabies virus. Nat. Methods 2007, 4(1):47-49.
126. Wickersham I.R., Lyon D.C., Barnard R.J., Mori T., Finke S., Conzelmann K.K., Young J.A., Callaway E.M. Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 2007, 53(5):639-647.
127. Wirblich C., Schnell M.J. Rabies virus glycoprotein expression levels are not critical for pathogenicity of RV. J. Virol. 2011, 85:697-704.
128. Wirblich C., Tan G.S., Papaneri A., Godlewski P.J., Orenstein J.M., Harty R.N., Schnell M.J. PPEY motif within the rabies virus (RV) matrix protein is essential for efficient virion release and RV pathogenicity. J. Virol. 2008, 82(19):9730-9738.
129. Yamada K., Ito N., Takayama-Ito M., Sugiyama M., Minamoto N. Multigenic relation to the attenuation of rabies virus. Microbiol. Immunol. 2006, 50(1):25-32.
130. Zhao L., Toriumi H., Kuang Y., Chen H., Fu Z.F. The roles of chemokines in rabies virus infection: Overexpression may not always be beneficial. J. Virol. 2009, 83(22):11808-11818.
131. Zhao L., Toriumi H., Wang H., Kuang Y., Guo X., Morimoto K., Fu Z.F. Expression of MIP-1alpha (CCL3) by a recombinant rabies virus enhances its immunogenicity by inducing innate immunity and recruiting dendritic cells and B cells. J. Virol. 2010, 84(18):9642-9648.